Last reviewed · How we verify
PLA + MTX switched to ABA+ MTX, DB
PLA + MTX switched to ABA+ MTX, DB is a T-cell costimulation inhibitor Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 3 development for Rheumatoid arthritis (as part of combination therapy with MTX), Polyarticular juvenile idiopathic arthritis. Also known as: Orencia.
Abatacept (ABA) is a T-cell costimulation inhibitor that blocks the interaction between antigen-presenting cells and T cells, reducing inflammatory immune responses when combined with methotrexate (MTX).
Abatacept (ABA) is a T-cell costimulation inhibitor that blocks the interaction between antigen-presenting cells and T cells, reducing inflammatory immune responses when combined with methotrexate (MTX). Used for Rheumatoid arthritis (as part of combination therapy with MTX), Polyarticular juvenile idiopathic arthritis.
At a glance
| Generic name | PLA + MTX switched to ABA+ MTX, DB |
|---|---|
| Also known as | Orencia |
| Sponsor | Bristol-Myers Squibb |
| Drug class | T-cell costimulation inhibitor |
| Target | CD80/CD86 (on antigen-presenting cells); CD28 (on T cells) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Abatacept selectively modulates T-cell activation by binding to CD80 and CD86 on antigen-presenting cells, preventing engagement with CD28 on T cells. This blocks the second signal required for full T-cell activation and proliferation. When combined with methotrexate, a disease-modifying antirheumatic drug (DMARD), the dual mechanism provides enhanced suppression of inflammatory pathways in autoimmune conditions.
Approved indications
- Rheumatoid arthritis (as part of combination therapy with MTX)
- Polyarticular juvenile idiopathic arthritis
Common side effects
- Infection (upper respiratory, urinary tract)
- Headache
- Nausea
- Dizziness
- Hypertension
Key clinical trials
- Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLA + MTX switched to ABA+ MTX, DB CI brief — competitive landscape report
- PLA + MTX switched to ABA+ MTX, DB updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about PLA + MTX switched to ABA+ MTX, DB
What is PLA + MTX switched to ABA+ MTX, DB?
How does PLA + MTX switched to ABA+ MTX, DB work?
What is PLA + MTX switched to ABA+ MTX, DB used for?
Who makes PLA + MTX switched to ABA+ MTX, DB?
Is PLA + MTX switched to ABA+ MTX, DB also known as anything else?
What drug class is PLA + MTX switched to ABA+ MTX, DB in?
What development phase is PLA + MTX switched to ABA+ MTX, DB in?
What are the side effects of PLA + MTX switched to ABA+ MTX, DB?
What does PLA + MTX switched to ABA+ MTX, DB target?
Related
- Drug class: All T-cell costimulation inhibitor drugs
- Target: All drugs targeting CD80/CD86 (on antigen-presenting cells); CD28 (on T cells)
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis (as part of combination therapy with MTX)
- Indication: Drugs for Polyarticular juvenile idiopathic arthritis
- Also known as: Orencia
- Compare: PLA + MTX switched to ABA+ MTX, DB vs similar drugs
- Pricing: PLA + MTX switched to ABA+ MTX, DB cost, discount & access